Recombinant Phospho-Cardiac Troponin I (Ser23, Ser24) Monoclonal Antibody (AN302104L)
For research use only.
| Verified Samples | Verified Samples in WB: Human heart |
| Dilution | WB 1:5000-1:10000 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, |
| Applications | WB |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Peptide. This information is proprietary to PTMab |
| Abbre | Phospho-Cardiac Troponin I (Ser23, Ser24) |
| Synonyms | CMH, RCM, TNNI, TNNC, troponin I, TNNI3, CMD1FF, CMD2A, CMH7, RCM1, TNNC1, cTnI, troponin I3 |
| Swissprot | |
| Calculated MW | 24 kDa |
| Observed MW |
25 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Cardiac myofibril, Cytosol |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Signal Transduction, Stem Cells, Cardiovascular, Developmental Biology |
| Clone No. | A828 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Cardiac troponin is composed of three subunits, namely cardiac troponin T (cTnT), cardiac troponin I (cTnI), and cardiac troponin C (cTnC).They collectively participate in the regulation of cardiac muscle contraction. The amino-terminal and carboxyl-terminal ends of cTnImolecules are prone to degradation through protein hydrolysis. Cardiac troponin I (cTnI) is an important regulatory factor that inhibits musclecontraction under normal circumstances. It binds to actin, preventing the interaction between actin and cardiac troponin C (cTnC), thusinhibiting muscle contraction. The phosphorylation status of cTnI can alter its affinity for actin, thereby influencing the regulation of musclecontraction. The serine residues at positions 22 and 23 of cTnI are susceptible to phosphorylation by protein kinase A, which regulatesmuscle contraction. Abnormal levels of phosphorylation may also contribute to muscle dysfunction or the development of heart disease. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
